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DOI 10.1016/j.ccr.2011.03.004SUMMARYGlioblastomas display cellular hierarchies containing tumor-propagating glioblastoma stem cells (GSCs).
STAT3 is a critical signaling node in GSC maintenance but molecular mechanisms underlying STAT3
activation in GSCs are poorly defined. Here we demonstrate that the bone marrow X-linked (BMX) nonrecep-
tor tyrosine kinase activates STAT3 signaling to maintain self-renewal and tumorigenic potential of GSCs.
BMX is differentially expressed in GSCs relative to nonstem cancer cells and neural progenitors. BMX knock-
down potently inhibited STAT3 activation, expression of GSC transcription factors, and growth of GSC-
derived intracranial tumors. Constitutively active STAT3 rescued the effects of BMX downregulation, sup-
porting that BMX signals through STAT3 in GSCs. These data demonstrate that BMX represents a GSC ther-
apeutic target and reinforces the importance of STAT3 signaling in stem-like cancer phenotypes.INTRODUCTION
Glioblastoma multiforme (GBM) is the most common and
lethal type of primary brain tumor with a median survival of
12-15 months despite optimal therapy (Furnari et al., 2007;
Wen and Kesari, 2008). GBM displays striking cellular hetero-
geneity and hierarchy in differentiation status. The fraction ofSignificance
Glioblastomas are highly lethal brain tumors containing self-re
invasion, and therapeutic resistance—each contributing to trea
specifically control the stem cell-like properties and tumorigen
into important therapeutics against these malignant tumors. G
bone marrow X-linked kinase (BMX), which maintains the stem
STAT3 signaling and regulating the expression of critical GSC
sents a potential target amenable to specific disruption for t
improve treatment of GBM.
498 Cancer Cell 19, 498–511, April 12, 2011 ª2011 Elsevier Inc.cancer cells at the apex of the hierarchy are called glioblastoma
stem cells (GSCs), functionally defined by extensive self-
renewal, multilineage differentiation potential and propagation
of tumors that recapitulate the tissue architecture and cellular
hierarchy of the parental lesion (Park and Rich, 2009; Rosen
and Jordan, 2009; Vescovi et al., 2006; Zhou et al., 2009).
We and others have demonstrated that GSCs interact withnewing cancer stem cells that promote tumor angiogenesis,
tment failure. The elucidation of molecular mechanisms that
ic potential of glioblastoma stem cells (GSCs) may translate
SCs preferentially express the nonreceptor tyrosine kinase
cell-like phenotype and tumorigenic potential by activating
transcription factors. These data suggest that BMX repre-
he development of effective therapeutics against GSCs to
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BMX Activates STAT3 to Maintain GBM Stem Cellsthe microenvironment to promote tumor angiogenesis, immune
evasion, and resistance to current therapies (Bao et al., 2006a,
Bao et al., 2006b; Calabrese et al., 2007; Gilbertson and Rich,
2007; Liu et al., 2006; Wei et al., 2010). GSCs share some crit-
ical characteristics with normal neural stem/progenitor cells
(NPCs), including expression of NPC markers and residing in
certain niches in vivo (Calabrese et al., 2007; Gilbertson and
Rich, 2007; Vescovi et al., 2006; Zhou et al., 2009). However,
GSCs are also significantly distinct from NPCs in many
aspects, including active proliferation, genetic abnormalities,
tumor formation, aberrant gene expression, and differential
hypoxia response in GSCs, suggesting that there are funda-
mental differences in the signaling pathways controlling stem
cell properties between GSCs and NPCs. Identification of
unique signaling regulators that control the phenotype and
tumorigenic potential of GSCs might provide new avenues for
developing effective therapeutics against GSCs to improve
GBM treatment.
The signal transducer and activator of transcription (STAT)
family of transcription factors provide important signaling nodes
downstream of extracellular regulators including cytokines
(Bromberg, 2002; Levy and Darnell, 2002). Among the STATs,
STAT3 prominently contributes to cellular transformation and
tumor maintenance (Bromberg et al., 1999; Chan et al., 2004;
Grivennikov et al., 2009), particularly in GBM (de la Iglesia
et al., 2009; Lo et al., 2008). A functional contribution of STAT3
in glioma growth was demonstrated in a number of studies (Das-
gupta et al., 2009; Rahaman et al., 2002). Activation of a STAT3-
mediated transcription network was recently associated with
mesenchymal GBM transformation and poor patient survival
(Carro et al., 2010). In addition to these effects, silencing
STAT3 in GBM cells induces cellular differentiation (Li et al.,
2009b), suggesting a role for STAT3 inmaintaining an undifferen-
tiated cellular state in tumors. Indeed, recent reports showed
that STAT3 is constitutively activated in GSCs and that targeting
STAT3 disrupts GSC maintenance (Sherry et al., 2009; Wang
et al., 2009).
The bone marrow X-linked kinase (BMX, also known as ETK)
is an intracellular nonreceptor tyrosine kinase that associates
with and activates STAT3 (Saharinen et al., 1997; Tsai et al.,
2000). BMX is a member of the Tec-family kinases character-
ized by the presence of several critical domains including the
Plekstrin homology (PH), the Tec homology (TH), the Src
homology SH3 and SH2, and the SH1 kinase domain (Smith
et al., 2001). This kinase is activated by several chemokines,
tumor necrosis factor receptor 2, vascular endothelial growth
factor receptors, ErbB3, and integrins (Chen et al., 2001; Jiang
et al., 2007; Pan et al., 2002). BMX is expressed in prostate
cancer and hepatocellular carcinomas and its overexpression
induced prostate neoplasia and skin hyperplasia (Dai et al.,
2006; Guo et al., 2007; Paavonen et al., 2004). Inactivation or
inhibition of BMX kinase markedly attenuates cell proliferation
and impairs Src-induced cell transformation (Paz et al., 2005).
In addition, BMX contributes to cancer cell resistance to radia-
tion and chemotherapy (Guo et al., 2010; Xue et al., 1999),
a phenotype associated with GSCs (Bao et al., 2006a; Liu
et al., 2006). However, BMX has not been investigated in
GSCs. Based on the functional importance of STAT3 in
GSCs, we investigated the potential role of BMX in STAT3activation and the maintenance of stem-like phenotypes in
GSCs.
RESULTS
BMX Is Differentially Expressed in GSCs Relative to
Nonstem Tumor Cells and NPCs
To assess whether BMX is expressed in a fraction of cancer
cells in primary GBM tissues, we performed immunohisto-
chemical (IHC) staining on tissue arrays containing 36 human
GBMs and 6 normal brain tissues. BMX was expressed in
a subpopulation of tumor cells in 32 of 36 (88.8%) GBMs but
none of normal brain tissues (Figure 1A; see Figure S1A and
Table S1 available online). In addition, BMX was strongly
expressed in a subpopulation of cancer cells in all seven
examined mouse GBMs from a well characterized genetically
engineered glioma model generated through the overexpres-
sion of PDGF in Nestin+ cells (Hambardzumyan et al., 2009)
(Figure 1B; Figure S1B). BMX expression was not detectable
in matched normal mouse brain tissues including the subven-
tricular zone (SVZ) that contains NPCs (Figure 1B; Figure S1B).
As the frequency of BMX-positive [BMX(+)] cells was similar to
that of GSCs in many studies, we performed immunofluores-
cent (IF) staining of BMX and GSC markers on frozen sections
of GBM xenografts or surgical specimens (known genetic alter-
ations in some GBMs are listed in Table S2). BMX was localized
to glioma cells expressing the GSC markers CD133, OLIG2,
and SOX2 (Figures 1C–1E), suggesting that BMX is preferen-
tially expressed in GSCs in GBMs. In addition, some BMX(+)
cells are proximal to blood vessels marked by anti-CD31
staining for endothelial cells in GBMs (Figure 1F; Figure S1C).
Quantification showed that a greater fraction of BMX(+) cells
reside in the close proximity (<5 mm) to the blood vessels rela-
tive to BMX() cells and the average proximity of BMX(+) cells
to endothelial cells is less than that of the BMX() cells (Figures
S1D–S1F). These data support the preferential expression of
BMX in GSC subpopulations that are often located in perivas-
cular niches in GBMs (Calabrese et al., 2007).
To address whether BMX plays a role in GSCs, we further
examined BMX expression in matched GSCs and nonstem
tumor cells isolated fromGBMsurgical specimens or xenografts.
BMX protein levels were elevated in GSCs enriched for the
CD133 surface marker relative to matched nonstem tumor cells
derived from five GBMs (Figure 2A, top panels). As BMX is
a kinase, we validated the activation of BMX in GSCs by
measuring its specific phosphorylation on Tyr40 [pBMX(Y40)]
(Figure 2A, middle panels). Because the utility of CD133 as
a marker for enriching GSCs is not uniform (Beier et al., 2007),
we examined BMX expression in GSCs enriched for CD15 (stage
specific embryonic antigen-1, SSEA-1), which is an alternative
GSC enrichment marker (Son et al., 2009). BMX expression
was also elevated in CD15-enriched GSCs from two GBM
specimens that did not express CD133 (Figure 2B). BMX was
coexpressed with several GSC markers (OLIG2, SOX2, and
CD133) (Figures 2C–2E; Figure S2). In addition, IHC staining
confirmedmore expression of BMX inGSCs than nonstem tumor
cells isolated from GBM tumors (Figure 2F). Collectively, these
data demonstrate that BMX is differentially expressed in GSCs
relative to nonstem tumor cells.Cancer Cell 19, 498–511, April 12, 2011 ª2011 Elsevier Inc. 499
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Figure 1. Expression of BMX in a Subpopu-
lation of Cancer Cells Expressing Stem Cell
Markers in GBMs
(A) Immunohistochemical (IHC) staining of BMX in
human primary GBMs and normal brain tissues.
BMX(+) cells (indicated by arrows) are shown in
brown. Sections were counterstained with hema-
toxylin to show nuclei.
(B) IHC staining of BMX in GBMs from a genetically
engineered mouse model and normal mouse
brains including the subventricular zone (SVZ).
BMX(+) cells (brown) are indicated by arrows.
(C–E) Immunofluorescent (IF) staining of BMX and
the GSCmarkers CD133 (C), OLIG2 (D), and SOX2
(E) on frozen sections of GBMs. BMX was labeled
in green, CD133, OLIG2, or SOX2 in red. Nuclei
were counterstained with DAPI (blue). Cells with
extensive overlap are marked with arrows.
(F) IF staining of BMX(+) cells (green) in relation to
blood vessels marked by CD31 staining for
endothelial cells (red) in GBMs. Nuclei were
counterstained with DAPI (blue). Asterisk denotes
vessel lumen.
See also Figure S1, Table S1, and Table S2.
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BMX Activates STAT3 to Maintain GBM Stem CellsAs GSCs share many characteristics with NPCs, we investi-
gated the relative expression levels of BMX in GSCs and
NPCs. We first interrogated two mouse gene expression data-
bases for the developing embryo (Edinburgh Mouse Atlas;
http://www.emouseatlas.org/emage/) and the brain (Allen Insti-
tute Brain Atlas database; http://mouse.brain-map.org) and
found that BMX was rarely expressed in normal tissues during
mouse development (Figure S3A) or any region of mouse brain
(Figure S3B). We then isolated NPCs from brains of adult and
developing mice and confirmed that BMX was not expressed
in NPCs and mouse brains at any stage (Figures S3C and
S3D). As NPCs are located in the SVZ germinal zones, we
directly examined BMX expression by immunofluorescent (IF)
staining in the developing and adult mouse brains and confirmed500 Cancer Cell 19, 498–511, April 12, 2011 ª2011 Elsevier Inc.that SVZs express the NPC marker SOX2
but not BMX (Figure 3A). To insure that
the expression patterns in mouse NPCs
extended to human NPCs, we compared
BMX expression in six GSC populations
and five NPC lines. Consistent with our
IHC studies, no NPC line expressed
BMX whereas all six GSC populations
expressed high levels of BMX protein
(Figures 3B–3D; Figures S3E–S3G).
GSCs and NPCs expressed their
common markers SOX2, OLIG2, Nestin,
and CD133 as expected (Figures 3B–3D;
Figures S3F and S3G). As GBMs may
also be lineage related to astrocytes, we
further examined BMX expression in
human and mouse astrocytes, and
detected minimal BMX expression in
these cells (Figures S3H–S3J). Taken
together, these data demonstrate that
BMX is preferentially expressed in GSCsbut not in NPCs or astrocytes. Thus, BMX may be a tractable
GSC target due to its differential expression in neoplastic but
not normal stem/progenitor cells.
BMX Is an Upstream Activator of STAT3 in GSCs
but Not in NPCs
As BMX regulates cellular physiology through activation of
STAT3 (Saharinen et al., 1997; Tsai et al., 2000), the elevated
BMX expression in GSCs may functionally link to STAT3 hyper-
activation in GSCs. To define the role of BMX in regulating
STAT3 activation in GSCs, we targeted BMX expression
using two short hairpin RNAs (shRNAs) directed against
nonoverlapping regions of BMX mRNA and then measured
STAT3 activation in GSCs and NPCs. BMX knockdown in
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Figure 2. Differential Expression of BMX in GSCs Relative to Nonstem Tumor Cells
(A) Immunoblot (IB) analysis of BMX protein and its activating phosphorylation [pBMX(Y40)] in CD133-enriched GSCs and matched CD133-depleted tumor cells
derived from five GBMs.
(B) IB analysis of BMX and the GSC marker OLIG2 in CD15-enriched GSCs and CD15-depleted tumor cells from two GBMs.
(C–E) IF staining of BMXwith several GSCmarkers including OLIG2 (C), OCT4 (D), and SOX2 (E) in GSCs. BMXwas labeled in green, OLIG2, OCT4, or SOX2 in red;
and nuclei were counterstained with DAPI (blue). GSCs were cultured as attached monolayers (C) and (D) or tumorspheres (E).
(F) IHC staining of BMX in cultured GSCs and matched nonstem tumor cells (Nonstem) from a primary GBM (CCF2045) and a xenograft (T3691).
See also Figure S2.
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Figure 3. Preferential Expression of BMX in
Human GSCs but Not in NPCs and Subven-
tricular Zone (SVZ) of Mouse Brains
(A) IF staining of BMX in SVZs, subependymal
zones (SEZs), and dentate gyrus (DG) in devel-
oping and adult mouse brains. Mouse brains were
stained for BMX (green) and a NPC marker SOX2
(red). Nuclei were counterstained with DAPI (blue).
*, ventricles; CC, corpus callosum.
(B) IB analyses of BMX, STAT3, pSTAT3(Y705),
OCT4, SOX2, and OLIG2 expression in three GSC
populations and four human NPC lines.
(C) IF staining of BMX (green) and the NPC marker
Nestin (red) in GSCs (T4121) and NPCs (EN-
StemA). Nuclei were counterstained with DAPI
(blue).
(D) IF staining of BMX (green) and SOX2 (red) in
three GSC populations and three humanNPC lines
(bottom panels). Nuclei were counterstained with
DAPI (blue).
See also Figure S3.
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BMX Activates STAT3 to Maintain GBM Stem CellsGSCs reduced activating phosphorylation of STAT3 [pSTAT3
(Y705)] (Figures 4A and 4B; Figures S4A and S4B). In addition,
BMX knockdown in CD15-enriched GSCs reduced activated
STAT3 (Figure S4C). In contrast, BMX shRNA (shBMX) did not
alter STAT3 activation in NPCs (Figures 4A and 4B; Figure S4A),
despite high levels of basal activation of STAT3. We comple-
mented these findings using a gain-of-function study. Ectopic
expression of a constitutively active BMX (Flag-BMX-C) (Wu
et al., 2001) increased STAT3 activation in GSCs but not NPCs
(Figure 4C). These data demonstrate that BMX plays a pivotal
role in STAT3 activation in GSCs but not in NPCs.
Disruption of BMX Impairs GSC Proliferation
and Self-Renewal
As BMX is preferentially expressed in GSCs to promote STAT3
activation, and STAT3 mediates important signals for maintain-
ing GSCs (Sherry et al., 2009;Wang et al., 2009), we interrogated
the requirement of BMX in GSC maintenance. The initial func-502 Cancer Cell 19, 498–511, April 12, 2011 ª2011 Elsevier Inc.tional link between BMX expression and
GSC maintenance was indicated by
a marked decrease in BMX levels during
GSC differentiation induced by serum or
withdrawal of growth factors (Figures 5A
and 5B; Figures S5A–S5D). To elucidate
the role of BMX in GSC maintenance,
we examined the effects of BMX knock-
down on GSC proliferation and self-
renewal. GSCs transduced with shBMX
proliferated at lower rate than GSCs with
the nontargeting (NT) control shRNA (Fig-
ure 5C; Figure S5E). In contrast, identical
shBMXs had little to no effect onmatched
nonstem tumor cells (Figure 5D; Fig-
ure S5F) and human NPCs (Figure 5E;
Figure S5G). Moreover, targeting BMX in
GSCs reduced the efficiency of neuro-
sphere formation (Figures 5F–5H and
Figures S5H–S5J), a standard in vitroassay to assess the self-renewal and proliferation capacity of
GSCs. In contrast, targeting BMX had no impact on neurosphere
formation of NPCs (Figure 5I). To further confirm the effect of tar-
geting BMX on GSCs, we introduced a dominant-negative BMX
(BMX-DN) with a kinase-dead mutation (Tsai et al., 2000) into
GSCs. Expression of BMX-DN in GSCs also inhibited GSC
growth in vitro (Figure 5J) and suppressed neurosphere forma-
tion (Figures S5K and S5L). These data demonstrate that target-
ing BMX specifically disrupted GSC maintenance.
Targeting BMX Suppresses GSC Tumor Growth
and Increases Survival of Mice Bearing Intracranial
GBM Xenografts
The most important property of GSCs is their potent ability to
propagate tumors in vivo. To address the requirement for BMX
in maintaining the tumorigenic potential of GSCs, we examined
the effects of BMX downregulation on tumor propagating
capacity of GSCs. GSCs transduced with shBMX or NT shRNA
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Figure 4. BMX Is Required for STAT3 Acti-
vation in GSCs but Not in NPCs
(A) IB analysis of activating phosphorylation of
STAT3 (Y705) and total STAT3 in GSCs derived
from the indicated GBMs and NPCs with BMX
knockdown by shBMX1 or shBMX2. NT shRNA,
nontargeting control shRNA.
(B) IF staining of phosphorylated STAT3 [pSTAT3
(Y705)] in GSCs and NPCs with BMX knockdown.
BMX was labeled in green, pSTAT3 in red, and
nuclei were counterstained with DAPI (blue).
(C) IB analysis of STAT3 activating phosphoryla-
tion and total STAT3 in GSCs and NPCs with
ectopic expression of a constitutively active BMX
with a Flag tag (Flag-BMX-C).
See also Figure S4.
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BMX Activates STAT3 to Maintain GBM Stem Cellswere transplanted into the brains of immunocompromised mice.
Animals bearing GSCs expressing shBMX displayed reduced
tumor formation and increased tumor latency and survival
relative to those bearing GSCs expressing NT shRNA (Figures
6A–6D). Necropsy of animals sacrificed simultaneously
32 days (T4121 GSCs) or 36 days (CCF2170 GSCs) after implan-
tation revealed that GSCs transduced with shBMX frequently
failed to generate tumors or have reduced tumor size relative
to GSCs expressing NT shRNA (Figure 6A). Histological analyses
confirmed that tumors developed and invaded into brains im-
plantedwith GSCs expressing NT shRNA (Figure 6B, left panels),
whereas no tumor or only small tumor nodules developed in the
brains implanted with GSCs transfected with shBMX (Figure 6B,
right panels) at these early time points. The expression of BMX in
a subpopulation of cancer cells in GBM tumors derived from
GSCs expressing NT shRNAwas confirmed by IHC staining (Fig-
ure 6C). Moreover, mice intracranially implanted with the GSCs
transduced with shBMX survived significantly longer than those
with GSCs transfected with NT shRNA (Figure 6D). Although
>90% of cells were successfully targeted with shRNAs (data
not shown), we found that BMX was still expressed in the tumors
with delayed growth derived from the GSCs infected with
shBMX lentiviruses (Figure S6), suggesting that the tumors that
grew after BMX targeting had escaped knockdown. In addition,Cancer Cell 19, 498–5overexpression of BMX-DN in GSCs
significantly increased the survival of
mice bearing GSC-derived GBM tumors
(Figure 6E). Taken together, these data
demonstrate that BMX is required for
maintaining the tumorigenic capacity of
GSCs in vivo, suggesting BMX might be
a useful therapeutic target.
BMX Is Required to Maintain
Expression of Stem Cell
Transcription Factors in GSCs but
Not in NPCs
AsBMX is critical tomaintain GSCpheno-
type in vitro and tumorigenic potential
in vivo, BMX may control GSC properties
regulated by key stem cell transcription
factors (SCTFs). Therefore, we examinedthe impact of BMX knockdown on the expression of a panel of
critical SCTFs commonly expressed by GSCs. SOX2, OLIG2,
OCT4, and NANOG were all reduced after transduction with
shBMX in GSCs (Figure 7A). ShBMX1 and shBMX2 displayed
different knockdown efficiencies that correlated with the extent
of effects on GSC transcription factor expression (Figure 7A,
left panels). These results were confirmed by IF staining of
BMX and OLIG2 in GSCs. ShBMXs decreased OLIG2 protein
levels in GSCs with greater efficiency in response to the more
potent shRNA, shBMX1 (Figure 7B), suggesting that downregu-
lation of these SCTFs by BMX knockdown is dose-dependent
and specific. In contrast, introduction of shBMXs into NPCs
had no effect on the expression of these key SCTFs (Figure 7A,
right panels), indicating that expressional regulation of these
transcription factors by BMX was specific to GSCs not NPCs.
These results are consistent with the data above showing that
BMX knockdown has little effect on STAT3 activation in NPCs
(Figures 4A and 4B ; Figure S4A). To further confirm the effect
of targeting BMX on expression of SCTFs in GSCs, we intro-
duced the BMX-DN into GSCs. Expression of BMX-DN in
GSCs reduced STAT3 activation and expression of GSC tran-
scription factors (Figure 7C). Furthermore, ectopic expression
of constitutively active BMX in D456MG nonstem tumor cells,
which had been shown to grow tumor in mouse brains when11, April 12, 2011 ª2011 Elsevier Inc. 503
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Figure 5. BMX Level Declines during GSC Differentiation and BMX Disruption Decreases GSC Proliferation and Tumorsphere Formation
(A) IB analysis of BMX expression during GSC differentiation. Protein levels of BMX, SOX2, and OLIG2 (GSC transcription factors), GFAP (astrocyte marker), and
MAP2 (neuronal marker) were examined during GSC differentiation induced by serum (10% FBS) at indicated times.
(B) IF staining of BMX (green) and the neuronal marker MAP2 (red) or the astrocyte marker GFAP (red) from day 0 to day 6 during GSC differentiation induced by
serum. Nuclei were counterstained with DAPI (blue).
(C–E) Effects of BMX knockdown with shBMX1 or shBMX2 on cell proliferation in GSCs (C), matched nonstem tumor cells (D), and human NPCs (17231) (E).
Cells (1 3 104 per well) transduced with shBMX or NT shRNA were plated in quadruplicate wells in stem cell media, and then counted at the indicated times
(day 0–day 12). Data are means ± standard deviation (SD) (n = 4). *p > 0.05; ***p < 0.001.
(F–H) Effects of BMX knockdown by shBMX1 or shBMX2 on GSC tumorsphere formation. Representative images of tumorspheres derived from GSCs expressing NT
shRNA,shBMX1,or shBMX2areshown (H).Quantificationshows reducedGSCtumorspherenumber (F) andsize (G)byshBMXs.Dataaremeans±SD (n=3). ***p<0.001.
(I) Effect of shBMX1 or shBMX2 on neurosphere formation of NPCs. The representative images of neurospheres derived from NPCs expressing NT shRNA,
shBMX1, or shBMX2 are shown.
(J) Effects of a dominant-negative BMX (BMX-DN) on cell proliferation of GSCs. Data are means ± SD (n = 4). *p < 0.002; ***p < 0.001.
See also Figure S5.
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Figure 6. Targeting BMX in GSCs Sup-
pressed Tumor Growth and Increased
Survival of Animals Bearing Intracranial
GBMs
Effects of targeting BMX on GBM tumor growth
and animal survival were examined in the intra-
cranial xenograft model. GSCs from indicated
GBMs were transduced with NT shRNA, shBMX1,
BMX-DN, or vector control through lentiviral
infection, and then intracranially transplanted into
the brains of immunocompromised mice (5 3 103
cells per mouse). Mouse brains implanted with
GSCs expressing NT shRNA or shBMX were har-
vested simultaneously to examine the impact of
BMX disruption on GBM tumor growth (A–C). In
the animal survival experiments (D) and (E), mice
implanted with GSCs expressing NT shRNA,
shBMX, BMX-DN, or vector control were main-
tained until the development of neurological signs
or for 180 days.
(A) Representative images of cross sections
(hematoxylin and eosin [H&E] stained) of mouse
brains harvested on day 32 (T4121 GSCs) or day
36 (CCF2170 GSCs) after transplantation of GSCs
expressing NT shRNA or shBMX. Arrows indicate
large tumors in the brains with GSCs expressing
NT shRNA, or small tumors in the brains with GSCs
expressing shBMX.
(B) Histological analysis of brain tumors derived
from GSCs expressing NT shRNA or shBMX.
Green arrows indicate cancer cells invading into
normal tissue in brains implanted with GSCs ex-
pressing NT shRNA. A black arrow indicates
a small tumor nodule in the brain implanted with
GSCs expressing shBMX1.
(C) IHC staining of BMX in GBMxenografts derived
fromGSCs expressing NT shRNA. Arrows indicate
the representative BMX(+) cells (brown). Sections
were counterstained with hematoxylin.
(D) Kaplan-Meier survival curves ofmice implanted
with GSCs expressing shBMX1, shBMX2, or NT
shRNA. *p < 0.001.
(E) Kaplan-Meier survival curves of mice implanted
with GSCs transfected with a dominant-negative
BMX (BMX-DN) or vector control. **p < 0.001.
See also Figure S6.
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increased STAT3 activation (Figure 7D), induced expression of
GSC transcription factors including NANOG, BMI1, KLF4, and
OCT4 (Figure 7E), enhanced in vivo tumor growth (Figure 7F),
and significantly reduced the survival of mice bearing these cells
(Figure 7G), suggesting that BMX expression may promote the
acquisition of cancer stem cell phenotypes. In contrast, ectopic
expression of active BMX in NPCs did not enhance the high
baseline activation of STAT3 and expression of SCTFs (Fig-
ure S7A) and neurosphere formation (Figure S7B). BMX overex-
pression alone in NPCs did not cause oncogenic transformation
or tumor formation in vivo (data not shown). Taken together, our
data demonstrate that BMX preferentially regulates the expres-
sion of key SCTFs in GSCs but not in NPCs, suggesting that
the signaling pathway controlling the ‘‘stemness’’ might be
different between GSCs and NPCs despite shared similar stem
cell properties.Expression of a Constitutively Active STAT3 in GSCs
Rescues the Effects Caused by BMX Downregulation
To confirm STAT3 activation as the critical molecular mechanism
mediating BMX effects on expression of key SCTFs and the
maintenance of GSC phenotypes, we examined whether ectopic
expression of a constitutively active STAT3 (STAT3-C) (Brom-
berg et al., 1999) rescued the phenotypes caused by BMX down-
regulation. GSCs derived from primary GBMs were transduced
with Flag-tagged STAT3-C (STAT3-C-Flag) or EGFP (enhanced
green fluorescent protein) vector control. Expression of STAT3-
C-Flag in GSCs not only restored the growth and proliferation
but also rescued the impaired tumorsphere formation caused
by BMX knockdown (Figures 8A–8D). Moreover, ectopic expres-
sion of STAT3-C-Flag restored the expression of key SCTFs
reduced by BMX knockdown (Figure 8E), suggesting that BMX
controls expression of these transcription factors through
STAT3 activation. As BMX knockdown in GSCs significantlyCancer Cell 19, 498–511, April 12, 2011 ª2011 Elsevier Inc. 505
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Figure 7. BMX Regulates Expression of Stem Cell Transcription Factors in GSCs but Not in NPCs
(A) IB analysis of stem cell transcription factors (SCTFs) in GSCs and NPCs with BMX knockdown by shBMX1 or shBMX2. Cell lysates from the indicated GSCs
and NPCs expressing shBMX1, shBMX2, or NT shRNA were analyzed for protein levels of BMX, OLIG2, OCT4, SOX2, and NANOG.
(B) IF staining of OLIG2 (a GSC transcription factor) in GSCs expressing NT shRNA, shBMX1, or shBMX2. BMX was labeled in green, OLIG2 in red. Nuclei were
counterstained with DAPI (blue).
(C) IB analysis of STAT3 activating phosphorylation (pSTAT3-Y705) and expression of GSC transcription factors SOX2 and OLIG2 in GSCs expressing
a dominant-negative BMX (BMX-DN).
(D) IB analysis of STAT3 activation (pSTAT3-Y705) by expression of a constitutively active BMX (Flag-BMX-C) in D456MG nonstem tumor cells.
(E) RT-PCR analysis of mRNA expression of SCTFs including BMI-1, NANOG, OCT4, and KLF4 in D456MG nonstem tumor cells expressing the active
Flag-BMX-C. Data are means ± SD (n = 3). *p < 0.002.
(F) Effect of the active Flag-BMX-C on tumor growth of GBM xenografts derived from D456MG nonstem tumor cells. D456 nonstem tumor cells were transduced
with Flag-BMX-C or vector control, and then transplanted into the brains of immunodeficient mice via intracranial injection (23 106 cells per mouse). The brains
were harvested simultaneously on day 42 after cell transplantation. The representative images of brain cross sections (H&E stained) are shown. Tumors inside
brains are indicated by arrows.
(G) Kaplan-Meier survival curves of mice implanted with D456MG nonstem tumor cells transfected with the active Flag-BMX-C or control vector. D456 nonstem
tumor cells transduced with Flag-BMX-C or control vector were intracranially transplanted into brains of immunodeficient mice (2 3 106 cells per mouse). The
mice were maintained until the development of neurological signs or for 180 days. *p = 0.002 by log rank survival analysis.
See also Figure S7.
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Figure 8. Ectopic Expression of a Constitutively Active STAT3 in GSCs Rescued the Phenotypes Caused by BMX Downregulation
(A) Effects of a constitutively active STAT3 (STAT3-C-Flag) on cell proliferation of GSCs expressing NT shRNA or shBMX. GSCs (CCF2045) were transduced with
STAT3-C-Flag or vector control and then targeted with shBMX1 or NT shRNA. The relative increase (folds) of cell number from day 0 to day 4 among the four
groups (STAT3-C/Vector and shBMX1/NTshRNA) was compared. Data are means ± SD (n = 5). *p < 0.001.
(B–D) Effects of STAT3-C-Flag on tumorsphere formation of GSCs expressing NT shRNA or shBMX. Representative images of GSC tumorspheres derived from
GSCs transduced with STAT3-C-Flag or vector and targeted with shBMX1 or NT shRNA are shown (B). Quantification shows the effects of STAT3-C-Flag
expression on tumorsphere number (C) and size (D) of GSCs expressing NT shRNA or shBMX. Data are means ± SD (n = 4). *p < 0.001.
(E) IB analysis of GSC transcription factors (SOX2, OLIG2, OCT4, and NANOG) in CCF2045 GSCs transducedwith STAT3-C-Flag or control vector in combination
with shBMX or NT shRNA.
(F) Effects of STAT3-C expression on tumor growth of GSCs expressing shBMX or NT shRNA. GSCs (T3359) were transduced with STAT3-C-Flag or vector
control, and then infected with shBMX1 or NT shRNA lentiviruses. 48 hr after infection, cells were transplanted into the brains of immunocompromised mice.
Representative images of cross sections (H&E stained) of mouse brains from the indicated experimental groups harvested 32 days posttransplantation are
shown. Arrows indicate tumors in mouse brains.
(G) Kaplan-Meier survival curves of mice implanted with GSCs expressing STAT3-C or vector in combination with shBMX or NT shRNA. Four groups of mice
implanted with the GSCs were maintained until the development of neurological signs or for 180 days. The statistical analyses (p value) between each group are
shown under the figure.
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BMX Activates STAT3 to Maintain GBM Stem Cellsinhibited GBM tumor growth and increased animal survival, we
examined whether expression of STAT3-C restored the GSC
tumor growth. Forced expression of STAT3-C rescued in vivo
GSC tumor growth impaired by BMX downregulation (Figure 8F)
and attenuated the increased survival of mice bearing GSC-
derived tumors expressing shBMX (Figure 8G). Expression of
the STAT3-C in GSCs abolished the effects of shBMX on tumor
growth in vivo. These data demonstrate that BMX signals
through STAT3 to maintain the stem cell phenotype and tumor-
igenic potential of GSCs.
DISCUSSION
Despite recent advances in cancer therapies, patients diag-
nosed with GBM have had little improvement in their survival
over the past decades. The explanations for the failure of GBM
therapies are numerous, but a newly appreciated source of
complexity in tumor response is the presence of GSCs that
permit sustained tumor propagation. Recent studies support
the concept that many cancers, including GBMs, contain cellular
hierarchies in which not all cancer cells have equal potential to
propagate or maintain tumors (Gilbertson and Rich, 2007;
Lobo et al., 2007; Rosen and Jordan, 2009). Thus, biologic
screens of cancer stem cells (CSCs) may yield effective pharma-
cologic therapies (Gupta et al., 2009; Zhou et al., 2009; Frank
et al., 2010). Optimal development of specific agents against
CSCs may involve targeting critical regulators or signaling path-
ways not shared by normal somatic stem cells, to prevent
unwanted toxicities to normal stem cells. In this study, we
demonstrate that the nonreceptor tyrosine kinase BMX activates
STAT3 signaling in GSCs but not in NPCs, indicating that BMX
may represent one such unique target for the development of
anti-GSC therapeutic agents. As BMX is preferentially expressed
in GSCpopulation that is only a small fraction of total cancer cells
within a GBM tumor, an analysis of BMX expression based on
gene expression profile of whole tumor tissues is unlikely to be
informative. As current expression databases such as Onco-
mine, TCGA and REMBRANDT describe the average character-
istics of expression profile of tumor tissues from glioma patients,
interrogation of these databases did not provide a conclusive
indication regarding the association of BMX expression and
patient survival.
We have found that BMX regulates STAT3 activation in GSCs
but not in NPCs and plays essential roles in maintaining the GSC
phenotype and tumorigenic potential. Through STAT3 signaling,
BMX controls the expression of key SCTFs, including SOX2,
OLIG2, NANOG and OCT4 in GSCs. A recent study demon-
strated that sufficient activation of Jak-STAT3 signaling is critical
for reprogramming to ground state pluripotency and essential for
the maintenance of embryonic stem cells (Yang et al., 2010). Our
data suggest that the upstream activator of STAT3 signaling
important for maintaining stem cell phenotypes may differ
between normal and neoplastic stem cells. The preferential
expression of BMX in GSCs and its role in maintaining GSC
phenotypes through STAT3 activation suggests that BMX kinase
may be a druggable target for GSCs. Although STAT3 is consid-
ered to be a potentially important signaling node in CSCs, it is
difficult to inhibit specifically as STAT3 serves important func-
tions in normal tissue homeostasis. In contrast, BMX has several508 Cancer Cell 19, 498–511, April 12, 2011 ª2011 Elsevier Inc.attractive aspects as a molecular target. First, kinases are rela-
tively amenable to targeting with lowmolecular weight inhibitors.
Clinical trials of kinase inhibitors (generally directed against
receptor tyrosine kinases) for GBM treatment have been largely
negative (reviewed in Sathornsumetee and Rich 2007), but these
inhibitors failed in GBMs due to redundancy in receptor binding
and signaling to intracellular mediators (Stommel et al., 2007). As
an intracellular signal transducer that integrates upstream
signaling, BMX may be attractive as its signaling may be more
specific in GSCs. Several signaling pathways feed into the acti-
vation of STAT3 in GSCs, including Notch, IL-6 (interleukin-6)
and PI3K (phosphoinositide-3-kinase) (Wang et al., 2009; Fan
et al., 2010). A recent study from our group demonstrated
that GSCs preferentially express both IL-6 coreceptors (IL6Ra
and gp130) and targeting IL6Ra expression reduced STAT3
activation and inhibited GSC survival and tumor growth (Wang
et al., 2009). Thus, it is enticing to believe that IL6R-mediated
signaling may activate BMX that in turn activates STAT3.
Although the upstream kinase that directly activates BMX in
GSCs has not been defined, BMX mediates critical activation
of STAT3 in GSCs suggesting that functional disruption of BMX
may attenuate multiple key signals involved in CSC growth
and survival. The toxicity of BMX inhibitors may be modest
as BMX is not expressed in NPCs and normal brain, and it is
dispensable in normal development and survival, as demon-
strated by a minimal phenotype in a knockout mouse model
(Rajantie et al., 2001).
CSCs are not cell autonomous but reside in defined functional
niches (Calabrese et al., 2007; Gilbertson and Rich, 2007; Lathia
et al., 2010). Previous studies suggested that BMX can addition-
ally mediate other effects associated with the GSC phenotype:
therapeutic resistance, invasion and angiogenesis. BMX expres-
sion has been linked to resistance to chemotherapy in prostate
and lung carcinoma cells (Guo et al., 2010; Xue et al., 1999).
BMX also facilitates integrin-mediated motility through interac-
tions with focal adhesion kinase (Chen et al., 2001), but direct
validation of a role of BMX in GSC-mediated cancer invasion is
yet to be determined. In addition, BMX may play an important
role in angiogenesis. Limb ischemia in BMX knockout mice led
to reduced recovery and angiogenesis, whereas BMX transgenic
mice overexpressing BMX displayed an accelerated angiogenic
response (He et al., 2006). BMX activation also stimulates VEGF
production (Chau et al., 2005). Thus, systemic inhibition of BMX
may not only directly target GSC self-renewal and growth but
may also disrupt the functional vascular niches that are essential
for GSC maintenance (Calabrese et al., 2007; Gilbertson and
Rich, 2007; Li Z et al., 2009). As we have demonstrated that
GSCs are an important source of VEGF (Bao et al., 2006b), it is
likely that BMX contributes to the ability of GSCs to support
angiogenesis as well. Inhibiting BMX in conjunction with anti-
angiogenic drugs (particularly VEGF antagonists) or conven-
tional radiation and/or chemotherapeutic therapies may achieve
elimination of GSCs with benefits against the tumor bulk.
Thus, BMX may offer antitumor activity with acceptable toxicity.
It is unlikely that anti-CSC therapies will be effective in isolation,
so the potential effects of BMX inhibition on angiogenesis and
therapeutic resistance may offer synergies. In conclusion, our
studies laid an essential foundation for the development of
BMX inhibitors as an anti-GSC therapy.
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Isolation and Culture of Glioma-Derived Cells
GSCs and nonstem tumor cells were isolated and characterized from GBM
xenografts or surgical specimens as previously described (Bao et al., 2006a;
Li et al., 2009a). De-identified GBM specimens were collected for this study
from Cleveland Clinic Brain Tumor and Neuro-Oncology Center in accordance
with an Institutional Review Board-approved protocol, and informed consent
was obtained from all GBM patients contributing tumor specimens. The
cancer stem cell phenotype of GSCs was confirmed by functional assays of
self-renewal (serial neurosphere passage), stem cell marker expression, differ-
entiation induction, and tumor propagation. Genetic changes of glioma cells
were determined by fluorescent in situ hybridization (FISH).
Immunoblot Analysis and Immunofluorescent Staining
Immunoblot (IB) analysis and immunofluorescent (IF) staining of cells and
tissues sections was performed as described (Bao et al., 2006a; Lathia
et al., 2010). Specific antibodies against BMX (ab59360, ab59288, Abcam;
or BD), phospho-BMX (Y40) (Cell Signaling), phospho-BMX-pY566
(ab59409, Abcam), CD133/1 (Miltenyi or Abcam), STAT3 and phospho-
STAT3 (pSTAT3-Y705) (Cell Signaling), SOX2 (RnD or Millipore), OLIG2
(RnD), Nestin (Abcam), GFAP and MAP2 (Sigma-Aldrich or Covance), NANOG
(Millipore), TRA-1-85 (RnD), Flag (M2, Sigma-Aldrich), OCT4 and a-tubulin
(Millipore or Santa Cruz) were used for IB analysis or IF staining.
Immunohistochemistry
Immunohistochemistry (IHC) staining of tumor and normal tissue sections was
done with an ABC kit using DAB (3,30-Diaminobenzine) detection (Vector Lab)
as previously described (Bao et al., 2006b). Two purified anti-BMX antibodies
(#610792, BD; ab59288, Abcam) were identified to stain specifically on paraffin
embedded sections. Tissue arrays containing 36 human GBM surgical speci-
mens and 6 normal brain tissues were provided by Dr. McLendon from Duke
Brain Tumor Center. The genetically engineered mouse GBM tumors (the
RCAS-PDGF Nestin-TVA system) were provided by Dr. Hambardzumyan in
our department.
Differentiation Assay
GSCs were cultured on Matrigel-coated coverslips or dishes and induced
for differentiation through withdrawal of EGF and bFGF growth factors or by
addition of serum (10% FBS in a-MEM). At indicated time points, cells were
harvested for immunoblot analysis or fixed for IF or IHC staining as described
above.
Human Neural Progenitor Cells and Astrocytes and the Isolation
of Neural Progenitor Cells and Astrocytes from Mouse Brains
Four human neural progenitor cell (NPC) lines (15167, 16934, 17231, and
17896 derived from fetal brains, Lonza) and one human embryonic stem
cell-derived NPC line (ENStemA, Millipore) were cultured and maintained in
suspension culture according to vendor’s instruction or propagated on the
BD stem cell Matrigel-coated dishes or coverslips in supplemented Neuro-
basal stem cell media. Human astrocytes (NHA) were also obtained from
Lonza. Murine NPCs were isolated from mouse brains and characterized as
described (Rietze and Reynolds, 2006). Mouse NPCs were isolated from
wild-type C57BL/6 mouse embryos and neonatal mice by dissociation of the
harvested forebrains with papain and DNaseI. Adult NPCs were derived
from 7- to 10-week-old C57BL/6mice bymicrodissection of the periventricular
region then digestion by papain and trypsin. Isolated NPCs were plated in
suspension culture in stem cell media and allowed to grow through three
passages to ensure self-renewal before harvesting for immunoblot analysis
or plating on coverslips for IF staining.
DNA Constructs and Lentiviral Transfection
Lentiviral clones expressing shBMX or NT shRNA (SHC002) were acquired
from Sigma-Aldrich. Two of five shBMXs (shBMX1 and shBMX2) that dis-
played high knockdown efficiency (80%–90% reduction) were used for all
related experiments. A lentiviral construct expressing constitutively active
BMX (Flag-BMX-C) was generated by cloning a DNA fragment corresponding
to BMX residues 243–675 into the XbaI and SalI sites of pLCMV-Flag-neovector (a gift of Dr. P. Chumakov at Cleveland Clinic) in frame with the
N-terminal Flag sequence. A point mutation leading to Lys-to-Gln substitution
in the active site of the kinase domain (corresponding to position 445 of BMX
protein) was introduced into the Flag-BMX-C construct to generate a dominant
negative BMX (BMX-DN). Mutagenesis was done using QuickChange Multi III
Site-DirectedMutagenesis kit (Stratagene) and confirmed by sequencing. Viral
particles were produced in 293T cells with the pPACK set of helper plasmids
(System Biosciences) in stem cell media. Viral stocks were concentrated by
precipitation with PEG-8000 and titered according to the manufacturer’s
instructions.
Rescue Experiments with the Constitutively Active STAT3
A constitutively active STAT3 (STAT3-C; Bromberg et al., 1999) retroviral
construct was generated by cloning the STAT3-C with a C-terminal Flag tag
into HindIII site within the pLEGFP-N1 vector (BD Biosciences). For rescue
experiments, GSCs were transduced with STAT3-C-Flag retroviral construct
or pLEGFP control vector, and allowed to recover for 48 hr. Neomycin-resis-
tant cells were selected by exposure to G418 for 7 days. Stable cells express-
ing STAT3-C-Flag or EGFP control were transduced to express either shBMX
or NT shRNA via lentiviral infection. 48 hr postinfection, cells were plated to
assess cell proliferation, self-renewal, and expression of stem cell factors, or
used for in vivo experiments.
Proliferation and Neurosphere Formation Assays
Cell proliferation and neurosphere/tumorsphere formation were measured as
previously described (Li Z et al., 2009; Lathia et al., 2010). All data were normal-
ized to day 0 and presented as mean ± standard deviation.
Quantitative RT-PCR
Total cellular RNA was isolated with an RNeasy kit (QIAGEN) and reverse
transcribed into cDNA using the Superscript III Kit (Invitrogen). Real-time
PCR was performed on an Applied Biosystems 7900HT cycler using SYBR-
Green Mastermix (SA Biosciences) with the following primers: OCT4: forward
50-GAGAACCGAGTGAGAGGCAACC-30 and reverse 50-CATAGTCGCTGCTT
GATCGCTTG-30; NANOG: forward 50-AATACCTCAGCCTCCAGCAGATG-30
and reverse 50-TGCGTCACACCATTGCTATTCTTC-30; c-MYC: forward 50-TC
AAGAGGCGAACACACAAC-30 and reverse 50-GGCCTTTTCATTGTTTTCC
A-30; BMI1: forward 50-CCAGGGCTTTTCAAAAATGA-30 and reverse 50-GCA
TCACAGTCATTGCTGCT-30; KLF4: forward 50-CCCAATTACCCATCCTT
CCT-30 and reverse 50-AGGTTTCTCACCTGTGTGGG-30; b-actin: forward
50-AGAAAATCTGGCACCACACC-30, and reverse 50-AGAGGCGTACAGGGA
TAGCA-30.
Intracranial Tumor Formation In Vivo
Intracranial transplantation of GSCs to establish GBM xenografts was per-
formed as described (Bao et al., 2006a; Li Z et al., 2009). GSCs were trans-
duced with NT shRNA or shBMX, and/or with BMX-DN or control vector
through lentiviral infection twice at a 24-hr interval. Twenty-four hours after
the second transduction, viable cells (53 103/animal or as indicated) were en-
grafted intracranially into athymic/nude or NOG (NOD/Shi-scid/IL-2Rgnull)
immunocompromised mice. For the survival experiments, animals were main-
tained until manifestation of neurological signs or for 180 days. To compare the
tumor growth, mouse brains implanted with GSCs expressing shBMX or NT
shRNA, BMX-DN, or control vector were harvested on same day as indicated
after GSC implantation. All animal procedures conformed to the Cleveland
Clinic IACUC-approved protocol.
Statistical Analysis
All grouped data are presented as mean ± standard deviation (SD). Difference
between groups was assessed by one-way analysis of variance (ANOVA) or
one-way ANOVA on ranks tests. All in vitro experiments were repeated at least
three times. For the in vivo experiments, log rank survival analysis was per-
formed. SigmaStat Software (Version 3.5) was used for all statistical analyses.
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